The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | Novel therapeutic options for Waldenström’s macroglobulinemia
The therapeutic potential for Waldenström’s macroglobulinemia (WM) is widening, with our growing understanding and knowledge of the genetics behind this disease. In this interview at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, reviews the current and prospective therapies available for WM. He highlights the exciting work being done with BTK inhibitors and monoclonal antibodies, including acalabrutinib, venetoclax and daratumumab, which are advancing the repertoire of targeted therapies.
